Simulations Plus

Simulations Plus Receivables

The Accounts Receivable of Simulations Plus (SLP) as of Oct 8, 2026 is 14.62 M USD. In the previous year, Accounts Receivable was 15.04 M USD — a change of -2.79% (lower).

Receivables

14.62 MUSD

YoY

-2.79%

Last updated:

Accounts Receivable of Simulations Plus is 2025 14.62 M USD. Accounts Receivable of Simulations Plus was 2024 15.04 M USD. It decreases by -2.79% lower compared to the previous year.

The Simulations Plus Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
7.50 M USD
Jan 1, 2019
8.30 M USD
Jan 1, 2020
10.50 M USD
Jan 1, 2021
13.00 M USD
Jan 1, 2022
13.80 M USD
Jan 1, 2023
10.20 M USD
Jan 1, 2024
15.04 M USD
Jan 1, 2025
14.62 M USD
The Simulations Plus Receivables history
YEARReceivablesYoY
14.62 MUSD-2.79%
15.04 MUSD+47.41%
10.20 MUSD-26.09%
13.80 MUSD+6.15%
13.00 MUSD+23.81%
10.50 MUSD+26.51%
8.30 MUSD+10.67%
7.50 MUSD+87.50%
4.00 MUSD+33.33%
3.00 MUSD+87.50%
1.60 MUSD-5.88%
1.70 MUSD—
Access this data via the Eulerpool API

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Simulations Plus stock

Accounts Receivable of Simulations Plus is 14.62 M USD in 2025.

Accounts Receivable of Simulations Plus changed from 15.04 M USD to 14.62 M USD, representing a -2.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Simulations Plus since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Simulations Plus historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Simulations Plus

All Key Metrics — Simulations Plus